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(HR: 1.47; 95% CI: 1.14-1.90; p¼0.003). The inﬂuence of these factors
varied over time (Table 1).
Table 1. Predictors of Early, Late and Very Late Intracoronary Thrombotic EventsVariables Early ITE HR [95% CI] Late ITE HR [95%CI]Very Late ITE HR
[95% CI]Patient Age
(per year increase)- - HR: 1.02
[1.00 – 1.04]Diabetes Mellitus - HR: 2.25
[1.46 – 3.47]-Arterial Hypertension HR: 1.50
[1.10 – 2.06]- -Previous PCI - HR: 2.30
[1.45 - 3.64]-First-generation DES - - HR: 1.64
[1.07 – 2.51]Number of Stents
implanted (per
additional stent)HR: 1.44
[1.32 – 1.58]- HR: 1.50
[1.24 – 1.82]ACC/AHA Type B2C
lesionsHR: 1.45
[1.08 – 1.95]HR: 2.02
[1.20 – 3.39]-CONCLUSIONS Multiple clinical, anatomical and procedural charac-
teristics were independently associated with the occurrence of ITEs,
with variable impact on early, late and very late ITE risk. First-gen-
eration DESs were associated with higher risk of very late ITE.
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BACKGROUND The novel drug-ﬁlled coronary stent (DFS; Med-
tronic, Inc., Santa Rosa, CA) is formed from a continuous tri-layered
wire with the innermost layer removed to create a hollow strut
lumen that functions as an internal drug reservoir. Small holes (w20
mm) are laser drilled into the abluminal side of the stent, and the
internal chamber is loaded with sirolimus. The DFS provides
controlled drug elution from an internally loaded drug platform
without utilization of a polymeric matrix, and thus may avoid
chronic inﬂammation and adverse vascular responses associated
with stents using polymer-based drug-release. A porcine coronary
model demonstrated complete stent strut coverage at 28 days
without inﬂammation. Clinical outcomes in humans with this device
have not yet been assessed.
METHODS The Clinical Evaluation of the Medtronic Polymer-Free
Drug-Eluting Coronary Stent System in De Novo Native Coronary Ar-
tery Lesions: REVascularization using a non-polymeric drug ELUTing
stent with Internal drug lOadiNg (RevElution Trial) is a ﬁrst-in-human
prospective, multicenter, non-randomized study of the DFS.
Approximately 100 subjects will be enrolled at 15 international sites
and followed through 5 years. Subjects with de novo lesions (single
lesion or two lesions in separate target vessels) in native coronary
arteries with a reference vessel between 2.25 and 3.50 mm in diameter
will be treated with the DFS. Baseline optical coherence tomography
(OCT) will be performed, and subjects will be assigned based on
sequence of enrollment into cohorts with different durations of paired
OCT follow-up at 1, 2, 3, and 6 months post implantation (15 subjects
in each), as well as at 9 and 24 months (30 subjects in each). In
addition to serial OCT imaging, other standard clinical and angio-
graphic/IVUS parameters will also be assessed.RESULTS AND CONCLUSIONS The DFS is designed to provide
controlled release of sirolimus through an internally loaded drug
platform, thus eliminating the need for a polymeric matrix. RevEl-
ution is the ﬁrst study to assess the vascular responses, efﬁcacy, and
safety of this novel device. One-month OCT outcomes from the Rev-
Elution study will be reported at TCT 2015, providing an early
assessment of neointimal coverage and stent apposition after DFS
implantation.
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BACKGROUND A novel drug-ﬁlled coronary stent (DFS; Medtronic,
Inc., Santa Rosa, CA) provides controlled drug elution from an inter-
nally-loaded drug platform without using a polymeric matrix, and
thus may avoid chronic inﬂammation and adverse vascular responses
associated with a polymer. The stent is formed from a continuous tri-
layered wire with the innermost layer removed to function as a
reservoir that elutes sirolimus from small holes (w20 mm) in the
abluminal side of the stent. The impact of the reservoir and holes on
mechanical properties of the stent and its radiopacity has not been
previously reported.
METHODS Stent integrity and mechanical strength with the DFS
were compared to the current generation Resolute OnyxTM drug-
eluting stent (DES, Medtronic, Inc.). Radial strength was tested by
measuring the force required to radially compress the stent (diam-
eter 3.0 mm) in a standard iris test. Longitudinal stent deformation
was tested by measuring the peak force required to compress the
stent by 1 cm after deployment in a 1.5 cm radius curved mock
vessel (3.0 x 18 mm). Results are reported as average  standard
deviation. Radiopacity was tested under ﬂuoroscopy in a porcine
coronary artery model.
RESULTS The DFS had greater radial strength as Resolute Onyx DES
(Figure upper left panel), and comparable resistance to longitudinal
deformation (Figure upper right panel). Under ﬂuoroscopy, the DFS
had greater radiopacity than the Integrity stentTM (Figure lower left
panel), and similar radiopacity as the Resolute Onyx and OmegaTM
stents (Figure lower right panel).
CONCLUSIONS The DFS utilizes an internally loaded drug platform to
provide controlled release of sirolimus without using a polymeric
matrix. Mechanical strength, as well as radiopacity, are at least com-
parable to current-generation DES. These in-house tests are being
independently validated and will be available for presentation at TCT
2015.
